These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12623165)

  • 1. Monocyte adhesion in diabetic angiopathy: effects of free-radical scavenging.
    Renier G; Mamputu JC; Desfaits AC; Serri O
    J Diabetes Complications; 2003; 17(2 Suppl):20-9. PubMed ID: 12623165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells.
    Renier G; Mamputu JC; Serri O
    Metabolism; 2003 Aug; 52(8 Suppl 1):13-8. PubMed ID: 12939734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of gliclazide on monocyte-endothelium interactions in diabetes.
    Renier G; Desfaits AC; Serri O
    J Diabetes Complications; 2000; 14(4):215-23. PubMed ID: 11004431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gliclazide decreases vascular smooth muscle cell dysfunction induced by cell-mediated oxidized low-density lipoprotein.
    Mamputu JC; Renier G
    Metabolism; 2001 Jun; 50(6):688-95. PubMed ID: 11398146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gliclazide decreases low-density lipoprotein oxidation and monocyte adhesion to the endothelium.
    Renier G; Desfaits AC; Serri O
    Metabolism; 2000 Feb; 49(2 Suppl 1):17-22. PubMed ID: 10693915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL.
    Desfaits AC; Serri O; Renier G
    Metabolism; 1997 Oct; 46(10):1150-6. PubMed ID: 9322798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment.
    Desfaits AC; Serri O; Renier G
    Diabetes Care; 1998 Apr; 21(4):487-93. PubMed ID: 9571329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gliclazide reduces the induction of human monocyte adhesion to endothelial cells by glycated albumin.
    Desfaits AC; Serri O; Renier G
    Diabetes Obes Metab; 1999 Mar; 1(2):113-20. PubMed ID: 11220509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic endothelial dysfunction: effect of free radical scavenging in Type 2 diabetic patients.
    De Mattia G; Laurenti O; Fava D
    J Diabetes Complications; 2003; 17(2 Suppl):30-5. PubMed ID: 12623166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular benefits of gliclazide beyond glycemic control.
    Jennings PE
    Metabolism; 2000 Oct; 49(10 Suppl 2):17-20. PubMed ID: 11078471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants.
    Mamputu JC; Renier G
    J Leukoc Biol; 2004 Jun; 75(6):1062-9. PubMed ID: 15020646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FNDC5 inhibits foam cell formation and monocyte adhesion in vascular smooth muscle cells via suppressing NFκB-mediated NLRP3 upregulation.
    Zang YH; Chen D; Zhou B; Chen AD; Wang JJ; Gao XY; Chen Q; Li YH; Kang YM; Zhu GQ
    Vascul Pharmacol; 2019 Oct; 121():106579. PubMed ID: 31319161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oral anti-diabetic agent, gliclazide, inhibits oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells.
    Li L; Renier G
    Atherosclerosis; 2009 May; 204(1):40-6. PubMed ID: 18801483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide.
    Mamputu JC; Renier G
    J Diabetes Complications; 2002; 16(4):284-93. PubMed ID: 12126787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
    Jennings PE; Belch JJ
    Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophilin A enhances macrophage differentiation and lipid uptake in high glucose conditions: a cellular mechanism for accelerated macro vascular disease in diabetes mellitus.
    Ramachandran S; Vinitha A; Kartha CC
    Cardiovasc Diabetol; 2016 Nov; 15(1):152. PubMed ID: 27809851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro.
    O'Brien RC; Luo M
    Metabolism; 1997 Dec; 46(12 Suppl 1):22-5. PubMed ID: 9439554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An endothelial cell adhesion protein for monocytes recognized by monoclonal antibody IG9. Expression in vivo in inflamed human vessels and atherosclerotic human and Watanabe rabbit vessels.
    Calderon TM; Factor SM; Hatcher VB; Berliner JA; Berman JW
    Lab Invest; 1994 Jun; 70(6):836-49. PubMed ID: 8015288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edaravone attenuates monocyte adhesion to endothelial cells induced by oxidized low-density lipoprotein.
    Li Z; Cheng J; Wang L
    Biochem Biophys Res Commun; 2015 Oct; 466(4):723-7. PubMed ID: 26348774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of gliclazide, a sulphonylurea to influence the oxidative processes within the pathogenesis of diabetic vascular disease.
    Jennings PE
    Adv Exp Med Biol; 1994; 366():313-24. PubMed ID: 7771262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.